
12 great end-of-week recipes to use up bits and pieces
Donal's Real Time Recipes "We have all been there. That moment at the end of the week, where the kitchen is bare, and you need to make magic out of nothing," says TV chef, cookbook author and maestro of easy home cooking Donal Skehan. If you're nodding along in agreement, look no further. Here's a round-up of clever recipes, from Skehan and other great cooks, that give you delicious ways to use up bits and pieces from the fridge and pantry. The end of the week meal has never looked so good!
Donal Skehan's "seriously good" mac and cheese recipe is ideal for using up whatever's in the fridge. Swap the cauliflower for broccoli if you like, or add in any little bits of leftover veg, and use whatever bits and pieces of cheese you have. "Roast chook never goes to waste in my house as there are countless ways to produce new dishes from leftovers, like this yummy salad with soba noodles and a fragrant ginger dressing. I use snow peas and spring onions in my recipe but change it up depending on what you love and have on hand," says Justine Schofield of this easy meal.
This recipe from Silvia Colloca is a great way to use up leftover pasta (in any kind of sauce). All you need is eggs, milk, cheese and olive oil. Cooked on the stove-top, it's ready in 15 minutes.
Just as the name suggests, this curry (or soup!) recipe from Alexx Stuart is a great way to use up what you have on hand. "Don't be bound by my ingredients list – make this curry your own by using any limp veg. For a yummy soup, add another cup of stock, remove the cinnamon stick at the end, and blend on high for a few seconds," she says. Fried rice is such a good way to use up leftover rice. "I love fried rice and you can really pump it up with healthy vegetables when you make it at home. I've used leftover cooked ham in this version, but you can really add whatever you like to it, says Skehan of this easy and filling bowl.
"In my mind, soup is the final destination for anything you've got hanging out in your fridge. I can pretty much guarantee you that whoever's eating a nice hot bowl of this soup isn't going feel like they're eating this week's leftovers," says Mary Berg. This soup is a great way to use up leftover chicken and/or cooked sausage, cooked vegetables and any small amounts of herbs.
Who wouldn't love sitting down to this at the end of the week? This nourishing, comforting soup from Donal Skehan uses many pantry ingredients, along with plenty of vegetables, and the pasta cooks in the pot along with everything else. Serve with garlic toasts for a fantastic, filling and easy family meal.
Ready in just 15 minutes, this satisfying pasta dish brings together pantry staples including dried pasta, tinned tomatoes, stock powder and evaporated milk.
If you have yoghurt and self-raising flour on hand, you can make the easy pizza bases in this recipe and top it with whatever you like. The meat topping shown, inspired by Turkish pide, is delicious but the possibilities are endless, and it's a great way to use up what you have in fridge and pantry: Leftover roast veg; cold cuts or other leftover meat; various kinds of cheese; the last few sprigs of a bunch of herbs...
Adam Liaw's method for clearing piled-up bread: a savoury bread pudding complete with ham, cheese and spinach. He suggests making it for breakfast, but it also works brilliantly as a an end-of-week supper if you plan ahead (it needs to soak for at least 2 hours). This Italian family recipe embraces the spirit of pizza in a cheesy, tomato-y bake. Add some salad or cooked green veg to round out the meal. You could also add leftover veg to the bake.
Watch now
Share this with family and friends
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
10 hours ago
- News.com.au
Health Check: A ‘manageable headwind' as Trump slugs Europe with 15pc pharma tariff
European drug makers have been spared a threatened 200% US tariff Mach 7's new CEO wants to walk in customers' shoes Highlights from the quarterly reporting fiesta The European drug sector is exhaling a sigh of relief after the Trump administration's decision to include drugs in a sweeping 15% tariff on European goods. The Orange One had threatened drug imposts of up to 200%. In a statement, European Commission President Ursula von der Leyen confirmed pharma products would be included. The White House Fact Sheet – no, not alternative facts – describes a 15% tariff 'including on autos and auto parts, pharmaceuticals and semiconductors'. The process is subject to a so-called Section 232 investigation, which examines any national security implications. This is due to conclude on August 1. Endpoints News reports that the European Union exported US$212 billion of pharma products in 2024. These drugs include Botox, Keytruda and Ozempic. Ireland accounted for nearly a quarter of these shipments. Analysts at US investment bank TD Cowen dub the 15% tariff a 'manageable headwind'. Makers of branded drugs will fare better than generic providers, because of higher prices. Meanwhile Australian pharma companies are waiting to see how munificent the Prez is – or otherwise. Federal Health Minister Mark Butler notes the US position on drug tariffs has "changed a lot over the last couple of weeks". Our capitulation on US beef imports might help, but who can read the mind of Donald John Trump? Mach 7 says major US job is on track Radiology imager Mach7 Technologies' (ASX:M7T) new CEO Teri Thomas has reassured investors about the progress of a large, delayed contract with the US Veterans Health Administration. The job is to support the sprawling organisation's National Teleradiology Program. Mach 7 is part of a five-member consortium, providing its picture archiving and communications systems. Announcing the contract in July 2023, the company said the phase one rollout potentially was worth $11.7 million over three years, This rises to $47.9 million for the second five-year phase. The system was meant to have cranked up by December last year and Thomas hopes this will happen later this year. 'It's progressing,' Thomas says. 'It's big, it's complicated and we are one of a number of vendors who need to come together for this solution to go live.' Quarterly progress Meanwhile, Mach 7 has chalked up its third successive quarter of positive cash flow, achieving $600,000 for the period and $700,000 for the year. The US-focused Mach 7 reported June quarter receipts of $8.4 million, 20% lower owing to 'timing differences' (March quarter receipts were 28% higher). As of June 30, contracted annual recurring revenue stood at $30.2 million, up 1.6% with 'growth from expansions and renewals offset by customer attrition'. Mach 7 has $23.1 million cash and no debt. Unusually for a biotech, Mach 7 has been undertaking a share buyback, having acquired $2.2 million of its own shares in the June half. This reflects management's belief that that Mach 7's modest $100 million market cap undervalues the company. Mach 7 shares have lost one-third of their value over the last year, including 8% this morning. In her maiden investor outing, Thomas this morning spoke of 'getting in the mind of customers and chucking on their shoes'. If Thomas the Tank Engine builds a head of steam, things could turn around quickly. Aroa affirms current-year guidance After a barren couple of weeks, we're being deluged with quarterlies – and far too many to scrutinise properly. As with Mach 7, Kiwi wound repair house Aroa Biosurgery (ASX:ARX) reported its third successive quarter of positive cash flow, of NZ$1.7 million. The company also managed receipts of NZ$22.5 million, driven by sales of its Myriad range for large complex wounds. Aroa has guided to revenue of NZ$92-100 million for the year to March 2026, with normalised underlying earnings of NZ$5-8 million. Cancer imaging house Imagion Biosystems (ASX:IBX) says it's on track to file an Investigation New Drug (IND) application with the FDA in the current quarter. If the agency grants the IND, Imagion can kick off a clinical trial of its Magsense tech, for breast imaging. Magsense will be the first imaging tech to use targeted magnetic nanoparticles to tag and detect cancers. Imagion had June quarter cash outflows of $818,000, taking cash on hand to $883,000. The company expects outflows to reduce in the current quarter, as it reduces corporate costs. Clever Culture Systems (ASX:CC5) chief Brent Barnes says 2024-25 has been a 'turning point for the company, resulting in a major milestone towards becoming a sustainable operating business'. The company now has signed up five big pharma companies for its automated agar plate system APAS Independence. These are for environmental monitoring of sterile drug making facilities. The company cites a 'sales opportunity' of $40 million, based on existing customers purchasing 60 to 80 units. Clever Culture recorded receipts of $880,000 and net operating cash outflows of $248,000. Full year flows were positive to the tune of $1.16 million. Prescient wants some more On the fundraising front, cancer drug developer Prescient Therapeutics (ASX:PTX) has raised $6.8 million in a share purchase plan (SPP) and will now carry out a follow-on placement. Usually, companies do the placement before the SPP, but there are no hard and fast rules. The shares are on trading hold pending the unquantified placement, which will be done at 4 cents per share (an 11% discount). Prescient's mercifully slimmed-down program focuses on PTX-100, which is in phase II development. The world's only GGT-1 inhibitor in clinical development, PTX-100 has looked promising in early programs for blood and solid cancers. Yesterday, PainChek (ASX:PCK) said it had raised $7.5 million in a placement, partly to support a US rollout into the $580 million US nursing market. The company expects FDA clearance of its digital pain measurement app by early October. New and existing institutional, high net worth and sophisticated investors supported the raising. The company said net contracted licences increased to 110,000. Contracted annual recurring revenue came in at $5.4 million (up 10%). The placement funds also will support the company's rollout of an infant app locally. FDA U-turns on key drug decision In more news from our buzzing Washington desk, the FDA has allowed Sarepta Therapeutics to resume selling its Duchenne muscular dystrophy gene therapy to non-wheelchair bound patients. In response, shares in the Nasdaq-listed Sarepta bounded almost 50% overnight. The agency decided the death of a Brazilian boy was unrelated to the drug, Elevidys. But two older patients died earlier. Sarepta still can't supply the drug to non-ambulatory patients. Despite the share bounce, Sarepta shares still have lost 90% of their value over the last year.


Daily Telegraph
13 hours ago
- Daily Telegraph
Update on Nicole Kidman's application for Portugal residency
New details have emerged over Nicole Kidman's plans to acquire residency in Portugal. A source close to the 'Paddington' star said while she and husband Keith Urban plan to gain residency in Portugal, they will keep Nashville as their primary base, according to The couple – who share daughters Sunday Rose, 17, and Faith Margaret, 15 – already own a plush pad in Lisbon. 'Keith, Nicole and the girls will continue to live primarily in Nashville however they do own property in Portugal,' a source told the New York Post. MORE: Inside Meghan, Harry's Netflix deal disaster Real reason Ellen fled the US revealed Surprise fortune Hulk Hogan left behind Last week news broke that the Oscar-winning actress submitted her paperwork to the country's immigration agency. But notably absent from her application was Urban, whose name did not appear on any documents. However, The Post understands the country music star wasn't mentioned in any paperwork because he was unable to break away from touring at the time. 'Keith was unable to be in Portugal for this appointment as he is currently on tour in the US and it is mandatory for applicants to be physically present in order to apply for the visa,' a source told The Post. 'He is scheduled to submit his application at a later date that works with his tour schedule. 'While Nicole and Keith own a home in Portugal, their primary residence will continue to be in Nashville.' Since tying the knot in 2006, Kidman and Urban have divided their time between the US and Australia, which could soon see Europe thrown into the mix. The duo has accumulated an impressive international real estate portfolio. Over nearly two decades, the couple has purchased two penthouses in the exclusive North Sydney Latitude building, combining the two to make one huge condo. The pair's first joint purchase came one year after their wedding, when they signed on the dotted line for a 36-acre estate in Franklin, Tennessee, for $US3.8 million ($A5.36 million). The following year, they upgraded to a lavish mansion in Nashville's exclusive Northumberland community, which they added to the growing portfolio that already boasts properties in Manhattan, Sydney and New South Wales. Parts of this story first appeared in the New York Post and was republished with permission. MORE: Ex-wife 'issues': Bitter MJ dispute exposed Fortune left behind by Ozzy revealed DiCaprio's insane $35m ask exposed

News.com.au
a day ago
- News.com.au
Save $284 on this Dyson Airwrap Multi-styler and Dryer
The winter mid-year slump is well and truly here, and if you're feeling a little restless stuck indoors, you're not alone. But if you can't quite afford a Europe getaway with the rest of your Instagram feed, a little self-care goes a long way. And right now, the crazy good Dyson Airwrap multi-styler and dryer is a huge $284 off, down to just $565. What makes this deal even better? The brand new Dyson Airwrap Co-anda 2x is about to launch on July 30 for a whopping $999. While it comes with a few upgraded features, you're essentially saving nearly 50 per cent with this version. The best-selling device dries, curls, shapes, smooths and hides flyaways all with no heat damage. Featuring six different attachments for every style and hair type, it seriously is the hair tool to end all hair tools. checkout editor, Hannah Paine, previously tested the Airwrap and said it's a 'great investment' and '100 per cent worth it'. 'Plus, just the mere fact that the Airwrap can replace a blow dryer, straightening iron and curling tongs makes it worth purchasing, especially if you're someone who styles their hair frequently,' she said. Others also agree. The device has over 41,000 five-star reviews on the Dyson website plus thousands of social videos and posts. 'It was also really simple to use and I picked up the techniques needed for each attachment quite quickly thanks to video tutorials. It's easily the best, most versatile hair tool! Don't know what I'd do without it,' wrote one very impressed customer. Another wrote, 'Brought my Airwrap two weeks ago. Been looking at it for years trying to justify the cost then thought I'd just buy it. Wish I'd done it sooner, easy to use, great attachments, dries my hair so well & smooth. Definitely worth the cost.' So if you've been thinking about it, follow this reviewer's advice and buy now. Sign up to our weekly shopping newsletter to get all the best deals, shopping tips and guides delivered straight to your inbox.